Protocol Single compound
CJC-1295 DAC
GHRH analog with Drug Affinity Complex
GHRH analog bearing a maleimide albumin-binding group (DAC), referenced in GHRH-receptor research.
Compare side by side →Compared with:CJC-1295 DAC vs Ipamorelin
Laboratory reference · in vitro research data
- Research vial sizes
- 2 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 2 mg | 1 mL | 2 | 0.2 |
| 2 mg | 2 mL | 1 | 0.1 |
| 2 mg | 3 mL | 0.67 | 0.067 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Syringe
Research dossier · published literature summary
01
Mechanism of action
CJC-1295 is a GHRH analogue carrying a drug affinity complex (DAC) that binds albumin after injection, extending its half-life to days. It stimulates pituitary GHRH receptors and raises GH and IGF-1.
02
Observed research endpoints
- Two randomized placebo-controlled trials in healthy adults: a single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days.
- Estimated half-life was 5.8–8.1 days; after repeated doses IGF-1 stayed above baseline for up to 28 days.
- GH pulsatility was preserved: trough GH rose 7.5-fold, mean GH rose 46% and IGF-1 rose 45%, with pulse frequency and size unchanged.
03
Regulatory & safety context
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- No serious adverse reactions were reported in the healthy-adult trials, which were small and short.
04
Citations
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.2006-03Randomized placebo-controlled trials (healthy adults)Read paper ↗
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.2006-12Clinical study (healthy adults)Read paper ↗
Keep exploring
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
View productView COA
Supplier C
TBDPlaceholder — details coming soon
View productView COA